Zobrazeno 1 - 10
of 178
pro vyhledávání: '"Gareth J, Veal"'
Autor:
Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Lucinda Griffiths, Cathy Qi, Matthew Parkes, Simon Lord, Gareth J. Veal, David J. Harrison, Vicky M. Coyle, Jill Graham, Thomas R. Jeffry Evans, Sarah P. Blagden
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)
Abstract Purpose 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a ph
Externí odkaz:
https://doaj.org/article/8de199adb6da4ff4b44e74190f835493
Autor:
David Damoiseaux, Frédéric Amant, Jos H. Beijnen, Shelby Barnett, Gareth J. Veal, Alwin D. R. Huitema, Thomas P. C. Dorlo
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1931-1944 (2023)
Abstract Limited information is available concerning infant exposure and safety when breastfed by mothers receiving chemotherapy. Whereas defining distribution to breast milk is important to infer drug exposure, infant pharmacokinetics also determine
Externí odkaz:
https://doaj.org/article/af9a165e42b342d1ae831f5b5ee8be77
Autor:
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. Veal, Christopher J. Corrigan, Stephen J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. Bax, Debra H. Josephs, Sophia N. Karagiannis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT025
Externí odkaz:
https://doaj.org/article/10c6fe5134614037a52da348794ee12d
Autor:
Sarah Johnson, Geoff Shenton, Ruth Plummer, Joshua Savage, Gareth J Veal, Julie Irving, Lucinda Billingham, Pamela Kearns, Daniel Slade, Tobias Menne, Britta Vormoor, Josef Vormoor
Publikováno v:
BMJ Open, Vol 12, Iss 3 (2022)
Introduction Event-free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30%–50%, with 5-year survival for adult patients only 20%. Many patients with newly diagnosed and relapsed A
Externí odkaz:
https://doaj.org/article/b59e18f2d4664a4b942cd501f73730b6
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
The utility of Therapeutic Drug Monitoring (TDM) in the setting of childhood cancer is a largely underused tool, despite the common use of cytotoxic chemotherapeutics. While it is encouraging that modern advances in chemotherapy have transformed outc
Externí odkaz:
https://doaj.org/article/76420c0bde3448d0a0a4956ac029ca68
Autor:
Sarah Halford, Gareth J. Veal, Stephen R. Wedge, Geoffrey S. Payne, Chris M. Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M. Salisbury, Maxime Chénard-Poirier, Alastair Greystoke, Elizabeth C. Howell, William A. Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C. Keun, Udai Banerji, Ruth Plummer
Publikováno v:
Clin Cancer Res
Purpose: Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-clas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46578631c1f8cdcae05d3e1c1e8c2c2
https://doi.org/10.1158/1078-0432.ccr-22-2263
https://doi.org/10.1158/1078-0432.ccr-22-2263
Autor:
Susan Fischer-Huchzermeyer, Levan Chikobava, Verena Stahn, Monique Zangarini, Philip Berry, Gareth J. Veal, Volker Senner, Victor F. Mautner, Anja Harder
Publikováno v:
BMC Research Notes, Vol 11, Iss 1, Pp 1-7 (2018)
Abstract Objective Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas characterized by high recurrence rates and early metastases. These tumors arise more frequently within neurofibromatosis type 1 (NF1) and present with resista
Externí odkaz:
https://doaj.org/article/c74417432a5744da97ad07a15fed69b0
Publikováno v:
Bioanalysis. 14:1241-1249
Background: HMBD-001 is an IgG1 humanized monoclonal antibody specifically targeting HER3, a receptor highly expressed on cancer cells in certain tumors. A bioanalytical method was required to quantify HMBD-001 in human serum, with high selectivity a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de748f62e37097b21f45fd440d9626b
https://doi.org/10.4155/bio-2022-0141
https://doi.org/10.4155/bio-2022-0141
Autor:
A. Laura Nijstad, Wan-Yu Chu, Evelien de Vos-Kerkhof, Catherine F. Enters-Weijnen, Mirjam E. van de Velde, Gertjan J. L. Kaspers, Shelby Barnett, Gareth J. Veal, Arief Lalmohamed, C. Michel Zwaan, Alwin D. R. Huitema
Publikováno v:
Pharmaceutical Research, 39(10), 2487-2495. Springer New York
Nijstad, A L, Chu, W-Y, de Vos-Kerkhof, E, Enters-Weijnen, C F, van de Velde, M E, Kaspers, G J L, Barnett, S, Veal, G J, Lalmohamed, A, Zwaan, C M & Huitema, A D R 2022, ' A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children ', Pharmaceutical Research, vol. 39, no. 10, pp. 2487-2495 . https://doi.org/10.1007/s11095-022-03364-1
Nijstad, A L, Chu, W-Y, de Vos-Kerkhof, E, Enters-Weijnen, C F, van de Velde, M E, Kaspers, G J L, Barnett, S, Veal, G J, Lalmohamed, A, Zwaan, C M & Huitema, A D R 2022, ' A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children ', Pharmaceutical Research, vol. 39, no. 10, pp. 2487-2495 . https://doi.org/10.1007/s11095-022-03364-1
Background Vincristine, a chemotherapeutic agent that extensively binds to β-tubulin, is commonly dosed at 1.4–2.0 mg/m2 capped at 2 mg. For infants, doses vary from 0.025–0.05 mg/kg or 50–80% of the mg/m2 dose. However, evidence for lower dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3252a80dc4a529e37c63fb381515ea87
https://doi.org/10.1007/s11095-022-03364-1
https://doi.org/10.1007/s11095-022-03364-1
Autor:
Claire Geurten, Julie Errington, Shelby Barnett, Hiten Patel, Saqib Noor, Vrinda Saraff, Gareth J. Veal, Susanne A. Gatz
Publikováno v:
Pediatric Blood & Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb1e7d20ba230e81c7c27d037616f8d8
https://doi.org/10.1002/pbc.30430
https://doi.org/10.1002/pbc.30430